M. Mitchell

发表

Effect of renal impairment on the pharmacokinetics of exenatide

P. Kothare, K. Mace, H. Linnebjerg, 2007, British journal of clinical pharmacology.

A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg/d oral olanzapine relative to 20 mg/d oral olanzapine in stable psychiatric subjects.

T. Hardy, M. Mitchell, E. Marquez, 2006, Clinical therapeutics.

Comparison of manual versus ambulatory blood pressure measurements with pharmacokinetic‐pharmacodynamic modeling of antihypertensive compounds: Application to moxonidine

D. Alwis, I. Trocóniz, M. Mitchell, 2000, Clinical pharmacology and therapeutics.

Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects

M. Mitchell, E. Lobo, M. Knadler, 2009, Journal of clinical pharmacology.

Current Status of the Ventak® PRx Pulse Generator and Endotak™ Nonthoracotomy Lead System

M. Mitchell, S. Nisam, M. Mower, 1992, Pacing and clinical electrophysiology : PACE.

Influence of a single dose of 20 mg tadalafil, a phosphodiesterase 5 inhibitor, on ambulatory blood pressure in subjects with hypertension.

G. Mcinnes, T. MacDonald, J. Webster, 2006, British journal of clinical pharmacology.

The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease.

R. Kloner, M. Effron, M. Warner, 2005, British Journal of Clinical Pharmacology.

Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects

M. Mitchell, E. Lobo, M. Knadler, 2009, Journal of clinical pharmacology.

Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects

P. Sager, Wenying Huang, B. Cirincione, 2012, British journal of clinical pharmacology.